FIELD: biotechnology; medicine.
SUBSTANCE: invention relates to biotechnology and medicine and represents an antibody or an antigen-binding fragment thereof, which specifically bind to hOX40L, where the antibody or antigen-binding fragment comprises a VH domain which contains: the sequence HCDR1 SEQ ID No: 36 or 42; sequence HCDR2 SEQ ID No: 38 or 44; and an HCDR3 sequence comprising VRGXYYY, where X is P, N, A or G; and wherein the antibody or antigen-binding fragment comprises a VL domain which comprises: sequence LCDR1 SEQ ID No: 50 or 56; sequence LCDR2 SEQ ID No: 52 or 58; and sequence LCDR3 SEQ ID No: 54 or 60. Combination of the antibody and an additional therapeutic agent is used to treat and/or prevent a hOX40L-mediated disease or condition.
EFFECT: invention enables effective use of the antibody for treating and/or preventing a hOX40L-mediated disease or condition.
44 cl, 7 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES, THEIR APPLICATION AND METHODS OF APPLICATION | 2016 |
|
RU2725221C2 |
| ANTI-TSLP ANTIBODY AND USE THEREOF | 2020 |
|
RU2834227C1 |
| BISPECIFIC ANTIBODY AND USE THEREOF | 2021 |
|
RU2839153C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| HUMAN CYTOMEGALOVIRUS ANTIBODY AND USE THEREOF | 2020 |
|
RU2817217C1 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| ANTI-SIRPα ANTIBODY AND USE THEREOF | 2021 |
|
RU2822496C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| C10orf54 ANTIBODIES AND USE THEREOF | 2015 |
|
RU2714232C2 |
